Home / Companies / News / Panacea forms JV with Refana to develop, manufacture Covid-19 vaccine

Panacea forms JV with Refana to develop, manufacture Covid-19 vaccine

The firm is set to make 500 million doses of the vaccine, which will then be supplied to the JV (based in the Republic of Ireland).

The government is now trying to understand how long it will take before the drug’s production can start in India

Premium

Half the 500 million doses will be made available in India. Panacea will start production of the trial batch by September.

Sohini Das Mumbai

2 min read Last Updated : Jun 10 2020 | 10:08 PM IST

Panacea Biotec, a New Delhi-based vaccine maker, has formed a 50:50 joint venture (JV) with Nasdaq-listed Refana to develop, manufacture, and market a potential cure for the virus.

Panacea’s shares jumped 20 per cent on Wednesday, closing at Rs 202.8 on the BSE. The firm is set to make 500 million doses of the vaccine, which will then be supplied to the JV (based in the Republic of Ireland). This will be a wholly inactive virus-based vaccine, which, according to Managing Director Rajesh Jain, is a robust an “time-tested technology”.

“We chose this over others because it is a robust, time-tested technology,

Topics : Coronavirus Panacea Biotech Vaccine Pharma Companies

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in